Esperion (ESPR) announced that following meetings with the U.S. Food and Drug Administration, it has gained alignment on a regulatory path ...

Esperion Therapeutics ESPR announced that it has come to an alignment with the FDA for initiating two phase III studies. The ...

Esperion Therapeutics declared that the US Food and Drug Administration (FDA) has approved a label expansion for two of its tablets, Nexletol (bempedoic acid) tablets and Nexlizet (bempedoic acid ...

Hyperuricemia: Bempedoic acid, a component of NEXLIZET and NEXLETOL ... The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily ...

The studies will evaluate bempedoic acid alone and in combination with ezetimibe in pediatric patients with heterozygous familial hypercholesterolemia (HeFH) and homozygous familial ...

for the exclusive rights to commercialize NEXLETOL ® (bempedoic acid) and NEXLIZET ® (bempedoic acid and ezetimibe) in Australia and New Zealand. Under the terms of the agreement, Esperion will ...

Hyperuricemia: Bempedoic acid, a component of NEXLIZET and NEXLETOL ... The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, ...